• About Us
  • Contact Us
Cure IBM
  • Home
  • IBM FAQ
  • Diagnosis
    • Introduction
    • Symptoms
    • Examination
    • Blood Tests
    • Electromyogram (EMG) and Nerve Conduction Studies
    • Magnetic Resonance Imaging (MRI)
    • Muscle Biopsy
    • Misdiagnosis
  • Treatment
    • Introduction
    • Medications
    • Clinical Trials
    • Exercise
    • Nutrition and Weight Control
    • Falls
    • Swallowing
    • Psychology
  • Resources
    • Links
    • Glossary
  • IBM Blog
  • Donate
Menu
Orphazyme Update Regarding Arimoclomol Clinical Trial During Coronavirus Pandemic

Orphazyme Update Regarding Arimoclomol Clinical Trial During Coronavirus Pandemic

by Kevin Dooley, MD | Mar 27, 2020 | News and Information

Thomas Blaettler, MD, the Chief Medical Office of Orphazyme, has released a statement to the global community regarding the status of the ongoing arimoclomol clinical trials during the coronavirus (COVID-19) pandemic. Arimoclomol is currently being studied for...
Arimoclomol Receives FDA Fast Track Designation for Inclusion Body Myositis

Arimoclomol Receives FDA Fast Track Designation for Inclusion Body Myositis

by Kevin Dooley, MD | Dec 18, 2019 | News and Information

Arimoclomol, an investigational drug currently in a Phase 2/3 trial for inclusion body myositis (IBM), has received Fast Track designation from the FDA for treatment of this disabling muscle disease. This designation is designed to shorten the time needed for the FDA...
Regeneron Cancels Clinical Trial of REGN2477 and REGN1033 for Inclusion Body Myositis

Regeneron Cancels Clinical Trial of REGN2477 and REGN1033 for Inclusion Body Myositis

by Kevin Dooley, MD | Mar 27, 2019 | News and Information

Regeneron Pharmaceuticals has confirmed the cancellation of its previously announced Phase 2 clinical trial for inclusion body myositis (IBM). Regeneron had planned to test two therapies in combination to treat this rare muscle disease, which causes gradually...
Running for Hope: Inspiration from Martin Jarry

Running for Hope: Inspiration from Martin Jarry

by Kevin Dooley, MD | Jan 1, 2018 | News and Information

His muscles are being destroyed by a disease called inclusion body myositis (IBM), but Martin Jarry is resilient. After recovering from the shock of his diagnosis, he began to fight back, working to increase public awareness of myositis and to bring hope to other...

Recent Posts

  • $68,245 Grant Available for Study of Inclusion Body Myositis
  • You can Bike, Walk, Run, or Ride for IBM on Saturday, June 13!
  • The Million Dollar Bike Ride Needs YOUR Help!
  • Orphazyme Update Regarding Arimoclomol Clinical Trial During Coronavirus Pandemic
  • Caution Regarding the Use of Chloroquine to Treat Coronavirus in Myositis Patients

Archives

  • August 2020
  • June 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • April 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017

Tags

accessible home advocacy arimoclomol asking for help autophagy awareness bimagrumab clinical trial clinical trials coping coronavirus exercise exoskeleton fundraising IBMFRS IB Myositis Inclusion Body Myositis Functional Rating Scale Jerry King Joe Sanchez kitchen laundry Living with IBM Martin Jarry MDBR Million Dollar Bike Ride mTOR myostatin patient story Patrick Warner personal story physical therapist physical therapy physiotherapist physiotherapy positive attitude psychology quality of life rapamycin Rare Disease Day research shoes support groups towel walking Yale IBM Registry
  • Disclaimer
  • Privacy Policy
  • Terms of Use
  • Facebook
  • Twitter

© 2021 Cure IBM | Website design and digital media services by Abaton Consulting

This website uses cookies to enhance user experience. By using our website, you agree to our Privacy Policy. Got it!